Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 3c, provides guidance

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q3 EPS of $0.17, $0.03 better than the analyst estimate of $0.14. Revenue for the quarter came in at $785 million versus the consensus estimate of $769.46 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2025 EPS of $0.75-$0.80, versus the consensus of $0.77. Amneal Pharmaceuticals sees FY2025 revenue of $3-3.1 billion, versus the consensus of $3.005 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance